Table 1. Clinical, demographic and anthropometric characteristics of participants included from the BREATHE trial.
| Controls (n=74) | Cases (n=336) | P-value | |
|---|---|---|---|
| Age at Enrolment, Mean (SD) | 14.9 (3.6) | 15.0 (3.2) | .833 |
| Female, N (%) | 46 (62.2) | 166 (49.4) | .063 |
| Zimbabwe, N (%) | 55 (74.3) | 241 (71.7) | .758 |
| Malawi, N (%) | 19 (25.7) | 95 (28.3)s | - |
| Height-for-Age z-score, Median (IQR) | -1.5 (1.0) | -2.1 (1.2) | < .001 |
| Stunted, N (%) | 22 (29.7) | 168 (50.0) | .002 |
| Weight-for-Age z-score, Median (IQR) | -1.1 (1.2) | -2.2 (1.5) | < .001 |
| Wasting, N (%) | 14 (18.9) | 176 (52.4) | < .001 |
| CD4+ T Cell Count, >350 Cells /mm3, N | 57 (78.1) | 252 (75.2) | .715 |
| HIV Viral Control (<200 copies/ml), N | 38 (51.4) | 145 (43.2) | .248 |
| Log-10 HIV Viral Load Copies/ml, | 2.0 (1.8) | 2.6 (2.5) | .087 |
| FEV1 Z-Score, Median (IQR) | 0.6 (0.5) | -2.0 (0.7) | < .001 |
| FEV1/FVC z-score, Mean (SD) | 0.2 (0.8) | -0.7 (1.1) | < .001 |
| FEV % Predicted, Mean (SD) | 107.7 (6.1) | 72.8 (9.9) | < .001 |
| Duration ART in Years, Median (IQR) | 6.5 (2.8) | 6.4 (3.2) | .758 |
| Ever Treated for TB, N (%)* | 9 (12.2) | 97 (29.9) | .005 |
| First Line Regimen - ATV/LPV/PI, N (%) | 66 (89.2) | 249 (74.1) | .009 |
| Second Line Regimen - EFV/NVP, N (%)* | 8 (10.8) | 87 (25.9) | - |
IQR = Interquartile Range, N= Number, ATV = Atazanavir, LPV=Lopinavir, PI= Protease inhibitor EFV= Efavirenz NVP = Nevirapine,
*
One data point missing
**
Two data points missing